Wolfgang Miesbach: How ‘Benign’ PDE Inhibitors Shape Platelet Function
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn about a recent article by Meinrad Paul Gawaz et al, published in ScienceDirect:
”Do ‘benign’ PDE inhibitors quietly shape platelet function?
A recent study by Meinrad Paul Gawaz and co-authors from the University of Tübingen investigates how different phosphodiesterase (PDE) inhibitors modulate platelet signalling and thrombus formation via cAMP/cGMP pathways.
What the authors explored
They compared:
- A broad PDE blocker
- A PDE‑3–preferring inhibito
- A PDE‑5 inhibitor
…across platelet activation, aggregation assays and a collagen flow‑chamber models:
- ADP/P2Y12‑ and TRAP/PAR1‑driven platelet responses are more sensitive to PDE inhibition than collagen/GPVI signalling.
- Robust inhibition of activation and aggregation requires broad or combined PDE targeting, rather than blocking a single isoform.
- Under arterial shear, all tested inhibitors – including a PDE‑5 blocker – reduce thrombus formation, revealing effects not seen in routine PRP assays.
Why this matters
For patients on chronic PDE‑3/5 therapy (e.g. for vascular disease, pulmonary hypertension, erectile dysfunction), there may be a ‘hidden’ antithrombotic modulation that becomes clinically relevant when combined with aspirin, P2Y12 inhibitors or DOACs.”
Title: Effect of phosphodiesterase inhibitors on platelet function
Authors: Ravi Hochuli, Valerie Dicenta, Zoi Laspa, Manuel Sigle, Tobias Harm, Tatsiana Castor, Anne-Katrin Rohlfing, Meinrad Paul Gawaz
Read the Full Article on ScienceDirect.

Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series